The global vulvodynia treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing awareness about the condition and its treatment, rising incidence of vulvodynia in women, and increasing number of women suffering from chronic pain.
The global vulvodynia treatment market is segmented on the basis of type into local anesthetics, anticonvulsants, tricyclic antidepressants, antimicrobials, hormone creams and nerve blocks. The local anesthetics segment accounted for the largest share in 2018 owing to their availability over-the-counter without prescription and ease of use. Anticonvulsants are expected to witness significant growth during the forecast period owing to their efficacy in treating chronic pain conditions such as vulvar vestibulitis syndrome (VVS). Tricyclic antidepressants are also expected to witness significant growth due to their efficacy in treating chronic pain conditions such as VVS. Antimicrobials are also expected to witness significant growth due to their efficacy against bacterial vaginosis which can cause inflammation or irritation around vagina or urethra that may lead towards development of vulvar vestibulitis syndrome (VVS). Hormone creams are also expected to witness significant growth due primarily because they help maintain healthy levels of estrogen which helps reduce symptoms associated with VVS like burning sensation while urinating or having sex etc, whereas nerve blocks are not recommended for long term use because they can cause numbness or tingling sensation around vagina or urethra which may lead towards development of VVS.
The global vulvodynia treatment market is segmented on the basis of application into hospital pharmacies and mail order pharmacies; retail pharmacies; other applications including clinics/hospitals/physicians’ offices; home care settings; other applications including gynecologists’ offices/urologists’ offices/gynecologists’ offices/urologists’ offices; other applications including general practitioners' office/general practitioners' office/. The hospital pharmacy segment accounted for the largest share in 2018 owing mainly due its availability over-the-counter without prescription and ease of use at hospitals where patients can get immediate relief from symptoms associated with VVS like burning sensation while urinating or having sex etc, whereas retail pharmacy accounted for second largest share owing mainly due its availability over-the-counter without prescription at retail stores where patients can get immediate relief from symptoms associated with VVS like burning sensation while urinating or having sex etc, whereas mail order pharmacy accounted for third largest share owing mainly due its convenience factor wherein patients do not have go out looking for it but instead just place an order online through a website where it will be delivered right at their doorstep within few days time frame wherein they do not have go out looking for it but instead just place an order online through a website where it will be delivered right at their doorstep within few days time frame wherein they do not have go out looking for it but instead just place an order online through a website where it will be delivered right at their doorstep within few days time frame wherein they do not have go out looking for it but instead just place an order online through a website where it will be delivered right at their doorstep within few days time frame.
-Vulvar pain is a common symptom of other conditions, such as endometriosis and pelvic inflammatory disease.
Industry Growth Insights published a new data on “Vulvodynia Treatment Market”. The research report is titled “Vulvodynia Treatment Market research by Types (Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, Antimicrobials, Hormone Creams, Nerve Blocks, Others), By Applications (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies, Others), By Players/Companies Pfizer Inc, Sanofi Aventis, Eli Lilly and Company, Depomed Inc, Janssen Pharmaceuticals, Noven Pharmaceuticals, Upsher-Smith Laboratories”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vulvodynia Treatment Market Research Report
By Type
Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, Antimicrobials, Hormone Creams, Nerve Blocks, Others
By Application
Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies, Others
By Companies
Pfizer Inc, Sanofi Aventis, Eli Lilly and Company, Depomed Inc, Janssen Pharmaceuticals, Noven Pharmaceuticals, Upsher-Smith Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Vulvodynia Treatment Market Report Segments:
The global Vulvodynia Treatment market is segmented on the basis of:
Types
Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, Antimicrobials, Hormone Creams, Nerve Blocks, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc
- Sanofi Aventis
- Eli Lilly and Company
- Depomed Inc
- Janssen Pharmaceuticals
- Noven Pharmaceuticals
- Upsher-Smith Laboratories
Highlights of The Vulvodynia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Local Anesthetics
- Anticonvulsants
- Tricyclic Antidepressants
- Antimicrobials
- Hormone Creams
- Nerve Blocks
- Others
- By Application:
- Hospital Pharmacies
- Mail Order Pharmacies
- Retail Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vulvodynia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for vulvodynia will vary depending on the individual's symptoms and medical history. However, some common treatments for vulvodynia include topical creams or ointments that are prescribed by a doctor, physical therapy to improve muscle function and flexibility in the pelvic area, pain relief medications such as ibuprofen or naproxen, and surgery if other treatments do not work.
Some of the major players in the vulvodynia treatment market are Pfizer Inc, Sanofi Aventis, Eli Lilly and Company, Depomed Inc, Janssen Pharmaceuticals, Noven Pharmaceuticals, Upsher-Smith Laboratories.
The vulvodynia treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vulvodynia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vulvodynia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vulvodynia Treatment Market - Supply Chain
4.5. Global Vulvodynia Treatment Market Forecast
4.5.1. Vulvodynia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vulvodynia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vulvodynia Treatment Market Absolute $ Opportunity
5. Global Vulvodynia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vulvodynia Treatment Market Size and Volume Forecast by Type
5.3.1. Local Anesthetics
5.3.2. Anticonvulsants
5.3.3. Tricyclic Antidepressants
5.3.4. Antimicrobials
5.3.5. Hormone Creams
5.3.6. Nerve Blocks
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vulvodynia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vulvodynia Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Mail Order Pharmacies
6.3.3. Retail Pharmacies
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vulvodynia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vulvodynia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vulvodynia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vulvodynia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vulvodynia Treatment Demand Share Forecast, 2019-2026
9. North America Vulvodynia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vulvodynia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vulvodynia Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Mail Order Pharmacies
9.4.3. Retail Pharmacies
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vulvodynia Treatment Market Size and Volume Forecast by Type
9.7.1. Local Anesthetics
9.7.2. Anticonvulsants
9.7.3. Tricyclic Antidepressants
9.7.4. Antimicrobials
9.7.5. Hormone Creams
9.7.6. Nerve Blocks
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vulvodynia Treatment Demand Share Forecast, 2019-2026
10. Latin America Vulvodynia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vulvodynia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vulvodynia Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Mail Order Pharmacies
10.4.3. Retail Pharmacies
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vulvodynia Treatment Market Size and Volume Forecast by Type
10.7.1. Local Anesthetics
10.7.2. Anticonvulsants
10.7.3. Tricyclic Antidepressants
10.7.4. Antimicrobials
10.7.5. Hormone Creams
10.7.6. Nerve Blocks
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vulvodynia Treatment Demand Share Forecast, 2019-2026
11. Europe Vulvodynia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vulvodynia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vulvodynia Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Mail Order Pharmacies
11.4.3. Retail Pharmacies
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vulvodynia Treatment Market Size and Volume Forecast by Type
11.7.1. Local Anesthetics
11.7.2. Anticonvulsants
11.7.3. Tricyclic Antidepressants
11.7.4. Antimicrobials
117.5. Hormone Creams
11.7.6. Nerve Blocks
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vulvodynia Treatment Demand Share, 2019-2026
12. Asia Pacific Vulvodynia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vulvodynia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vulvodynia Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Mail Order Pharmacies
12.4.3. Retail Pharmacies
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vulvodynia Treatment Market Size and Volume Forecast by Type
12.7.1. Local Anesthetics
12.7.2. Anticonvulsants
12.7.3. Tricyclic Antidepressants
12.7.4. Antimicrobials
12.7.5. Hormone Creams
12.7.6. Nerve Blocks
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vulvodynia Treatment Demand Share, 2019-2026
13. Middle East & Africa Vulvodynia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vulvodynia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vulvodynia Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Mail Order Pharmacies
13.4.3. Retail Pharmacies
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vulvodynia Treatment Market Size and Volume Forecast by Type
13.7.1. Local Anesthetics
13.7.2. Anticonvulsants
13.7.3. Tricyclic Antidepressants
13.7.4. Antimicrobials
13.7.5. Hormone Creams
13.7.6. Nerve Blocks
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vulvodynia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vulvodynia Treatment Market: Market Share Analysis
14.2. Vulvodynia Treatment Distributors and Customers
14.3. Vulvodynia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi Aventis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly and Company
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Depomed Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Janssen Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Noven Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Upsher-Smith Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
